Business Wire

Lexon’s Oblio Named as One of TIME’s 100 Best Inventions Of 2020

26.11.2020 10:57:00 EET | Business Wire | Press release

Share

20 years after making the cover of TIME with their flagship Tykho radio, French design brand Lexon is back on the prestigious publication to reiterate its mission to continuously create disruptive, useful and affordable design objects that improve our daily lives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005899/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Oblio (Photo: Business Wire)

More than just highlighting the groundbreaking French invention, TIME award confirms Oblio’s position as a must-have innovation for today’s world, as it has been crafted in-house primarily as a sleek UV-C sanitizer to prevent the spread of harmful viruses and bacteria that are found on our smartphones, using its built-in UV-C LED technology located on its front interior. UV-C LEDs destroy and eradicate the DNA of microorganisms found in viruses, bacteria, mold, and germs.

Capable of fully sanitizing a single surface at a time, Oblio can deliver a 360° disinfection by simply flipping the phone to expose its second surface for a 20-minute cycle. In terms of effectiveness, Oblio has been proven through lab testing to kill 99.9% of viruses, including H1N1.

Since the beginning of the pandemic, we have seen a growing interest for this product category (UV sanitizer) and therefore, the market becoming rapidly populated with lots of unaesthetic neither truly legitimate solutions. In this context, we're extremely honored and proud to be recognized and awarded for our product's distinct design, its effectiveness and reliability to sanitize our daily essentials and the opportunity to become a must-have solution for today's home and offices.

With the help of media like TIME who are raising awareness around Oblio, with the support and trust of our retail partners who are listing it, we are together making UV-C technology becoming more popular and accessible to everyone, allowing us to collectively participate in a positive change, leveraging innovation to adapt to new behaviors and prevent the spread of virus, which is our common responsibility.” Says Boris Brault, Lexon CEO.

Also acting as a 10W wireless charger, Oblio can fully charge a smartphone in 3 hours and comes with an LED indicator that confirms the correct positioning and charging status of the mobile device.

Appropriately, 'Oblio' is rooted in the Italian meaning for “forgot” the native language of designers’ Manuela Simonelli & Andrea Quaglio. The name hints to the product’s vase shape, thoughtfully crafted to help people disconnect from their screens and enjoy the freedom to be more present for each other, while discreetly sanitizing any mobile phone and fast-charging all Qi-enabled smartphones such as the latest iPhone and Android.

“With such achievements, we’re also proving that France remains an indisputable territory where creativity, innovation and design are prerequisite to sustainable growth, and we hope we can inspire entrepreneurs to believe in their projects and bring them to life.” adds Brault.

Today, Oblio is already available at the most prominent retailers worldwide such as Best Buy, Nordstrom, MoMA Design Store in the US, Fnac Darty in Europe and many more, as well as the official online store: lexon-design.com.

About Lexon:
Since its creation in 1991, Lexon has relentlessly pushed the limits and created a difference in the world of design while remaining true to its commitment to make small objects useful, beautiful, innovative and affordable. Whether in electronics, audio, travel accessories, office or leisure, Lexon has established a special relationship with creativity and partnered with the best designers around the world to create timeless collections of lifestyle products. Following its recent acquisition by BOW Group, a global player in the lifestyle and wearable consumer markets, Lexon is writing a new chapter in its history, experiencing a staggering international growth and digital expansion. Today, with nearly 30 years of existence, more than 200 awards, collaboration with some of the most renowned designers, a retail presence in more than 90 countries across the Globe, Lexon has truly established itself as a worldly-known French design brand.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

International Media contact:
Annabel Corlay a.corlay@lexon-design.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye